You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物-B(09926.HK)藥物獲納入CSCO宮頸癌診療指南
阿思達克 10-17 08:52
康方生物-B(09926.HK)公布,《中國臨床腫瘤學會(CSCO)宮頸癌診療指南(2022)》正式發布,由公司自主研發的全球首創PD-1/CTLA-4雙特異性抗體腫瘤免疫治療新藥開坦尼(R)(卡度尼利單抗注射液),作為復發或轉移性宮頸癌二線免疫治療首位推薦方案被納入指南。 公司指出,作為全球首個獲批上市的腫瘤雙免疫檢查點雙抗,卡度尼利是內地首個獲批上市的用於晚期宮頸癌治療的腫瘤免疫藥物,於6月底被國家藥監局批准上市,填補宮頸癌免疫治療的市場空白。卡度尼利獲批4個月即被CSCO寫入宮頸癌指南首選推薦,將有助於全國各地的臨床醫生更廣泛、深刻地理解卡度尼利的臨床療效,進而更快速、廣泛地滿足患者需求,改善生存獲益。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account